Immunocore reported Q4 2025 total revenue of USD 104.5 million, driven by KIMMTRAK net product revenue (net sales) of USD 104.5 million (+24.0%), and FY 2025 total revenue of USD 400.0 million, with KIMMTRAK net sales of USD 400.0 million (+29.0%). Q4 2025 net loss was USD 30.1 million and FY 2025 net loss was USD 35.5 million; Q4 basic and diluted loss per share was USD 0.60 and FY basic and diluted loss per share was USD 0.71. Cash, cash equivalents and marketable securities were USD 864.2 million as of December 31, 2025. KIMMTRAK was approved in 39 countries and launched in 30 countries for unresectable or metastatic uveal melanoma, with the company citing 13% year-over-year sales growth in the US and 79% year-over-year sales growth in Europe. Immunocore said it expects moderating revenue growth in 2026. In pipeline updates, Immunocore expects to complete enrollment in the Phase 3 TEBE-AM trial in 1H 2026 with topline overall survival data as early as 2H 2026; PRAME franchise Phase 1/2 data are expected in 2H 2026 (including brenetafusp in ovarian cancer and NSCLC, plus initial data for IMC-P115C), and additional Phase 1 HIV data are also planned for 2H 2026. The company filed a clinical trial application for IMC-S118AI in December 2025 and expects to begin its Phase 1 trial in 1H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250700PRIMZONEFULLFEED1001166605) on February 25, 2026, and is solely responsible for the information contained therein.